1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H1 2017, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 17, 7, 18 and 1 respectively. Similarly, the Universities portfolio in IND/CTA Filed and Discovery stages comprises 1 and 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 8
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 29
advanceCor GmbH 29
Akcea Therapeutics Inc 29
Amarantus Bioscience Holdings Inc 30
AnGes MG Inc 30
Arena Pharmaceuticals Inc 31
Ascendia Pharmaceuticals LLC 31
AstraZeneca Plc 32
Athera Biotechnologies AB 32
Bayer AG 33
Biscayne Pharmaceuticals Inc 33
Capricor Therapeutics Inc 34
Cardiome Pharma Corp 34
CardioVascular BioTherapeutics Inc 35
Cerenis Therapeutics Holding SA 35
CSL Ltd 36
Esperion Therapeutics Inc 36
Gilead Sciences Inc 37
HitGen LTD 37
Human Stem Cells Institute 38
Japan Tobacco Inc 38
Juventas Therapeutics Inc 39
Lee's Pharmaceutical Holdings Ltd 39
LipimetiX Development Inc 40
Lonestar Heart Inc 40
MedImmune LLC 41
Merck and Co Inc 41
Nuo Therapeutics Inc 42
Pfizer Inc 42
Pharmahungary Group 43
Proteon Therapeutics Inc 43
Resverlogix Corp 44
Tasly Pharmaceutical Group Co Ltd 44
The Medicines Company 45
Verseon Corp 45
VESSL Therapeutics Ltd 46
ViroMed Co Ltd 46
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles 47
4-WF - Drug Profile 47
AEM-28 - Drug Profile 48
AEM-2802 - Drug Profile 50
ALD-201 - Drug Profile 51
alprostadil - Drug Profile 53
AMRS-001 - Drug Profile 54
anacetrapib - Drug Profile 63
apabetalone - Drug Profile 65
AZD-5069 - Drug Profile 77
AZD-5718 - Drug Profile 79
beperminogene perplasmid - Drug Profile 80
Biologics for Acute Coronary Syndrome - Drug Profile 86
BIS-5409 - Drug Profile 87
bivalirudin - Drug Profile 88
cangrelor tetrasodium - Drug Profile 89
CAP-1002 - Drug Profile 93
CAP-2003 - Drug Profile 99
CER-001 - Drug Profile 101
clopidogrel bisulphate - Drug Profile 105
COR-2 - Drug Profile 106
Cryocell - Drug Profile 107
CSL-112 - Drug Profile 108
CVBT-141H - Drug Profile 110
dalcetrapib - Drug Profile 111
Gemacell - Drug Profile 115
Gene Therapy to Activate Vascular Endothelial Growth Factor for Coronary Artery Disease - Drug Profile 116
IONIS-APOARX - Drug Profile 117
JVS-100 - Drug Profile 120
MEDI-6012 - Drug Profile 125
MultiGeneAngio - Drug Profile 128
MZ-004 - Drug Profile 129
Neovasculgen - Drug Profile 131
PC-mAb - Drug Profile 132
PF-06282999 - Drug Profile 135
PMC-6 - Drug Profile 136
PR-15 - Drug Profile 137
Proteins for Ischemic Heart Disease - Drug Profile 139
ranolazine ER - Drug Profile 140
Recombinant Protein for Cardiovascular Diseases - Drug Profile 143
Rejuveinix - Drug Profile 144
rivaroxaban - Drug Profile 145
Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile 161
Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile 162
Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 163
temanogrel hydrochloride - Drug Profile 165
tirofiban hydrochloride - Drug Profile 167
TSL-0202 - Drug Profile 168
vericiguat - Drug Profile 169
VM-202 - Drug Profile 171
vonapanitase - Drug Profile 175
ZK-001 - Drug Profile 180
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 182
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 188
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 190
Featured News and Press Releases 190
Appendix 202
Methodology 202
Coverage 202
Secondary Research 202
Primary Research 202
Expert Panel Validation 202
Contact Us 202
Disclaimer 203

List of Tables
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by advanceCor GmbH, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Akcea Therapeutics Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Arena Pharmaceuticals Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Ascendia Pharmaceuticals LLC, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Athera Biotechnologies AB, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
1`
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cardiome Pharma Corp, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CSL Ltd, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Esperion Therapeutics Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by HitGen LTD, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Japan Tobacco Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by LipimetiX Development Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune LLC, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck and Co Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pfizer Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pharmahungary Group, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Proteon Therapeutics Inc, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Resverlogix Corp, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Verseon Corp, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by VESSL Therapeutics Ltd, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co Ltd, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017 (Contd..2), H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017 (Contd..3), H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, H2 2016

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, ...

Hypertriglyceridemia - Pipeline Review, H2 2016

Hypertriglyceridemia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Hypertriglyceridemia - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides ...

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.